골시멘트 및 접착제 시장 : 제품 유형, 기술, 용도, 최종사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Bone Cement & Glue Market was valued at USD 2.11 billion in 2025 and is projected to grow to USD 2.25 billion in 2026, with a CAGR of 6.58%, reaching USD 3.29 billion by 2032.

A clarifying introduction to how biomaterial innovation and clinical workflow evolution are redefining bone cement and surgical adhesive selection

The bone cement and adhesive landscape is experiencing heightened attention from clinical, regulatory, and commercial stakeholders as advances in biomaterials converge with evolving surgical workflows. This report opens with an oriented introduction that situates bone cement and glue within contemporary orthopedic, craniofacial, dental, and spinal care pathways, clarifying how variations in composition, delivery formats, and end-user settings influence adoption and clinical outcomes.

Clinical teams increasingly demand materials that balance handling characteristics with biological performance. Consequently, the sector's product mix now spans traditional polymethyl methacrylate (PMMA)-based cements and newer bioactive chemistries designed to support tissue integration or deliver localized therapeutics. Meanwhile, distribution and procurement models are being reshaped by the rise of group purchasing organizations, tender-driven hospital contracts, and direct manufacturer relationships that prioritize long-term value and supply resilience.

From a buyer's perspective, technology selection is influenced by procedural complexity, setting capabilities, and reimbursement dynamics, leading to differentiated uptake across hospital operating rooms, ambulatory surgical centers, and specialty clinics. As a result, stakeholders must evaluate product portfolios not only on primary performance metrics but also on sterilization, storage, and in-procedure workflow compatibility. This introduction frames those dynamics and sets expectations for the deeper analysis to follow.

How advances in biomaterials, procedural migration to outpatient settings, and elevated regulatory requirements are reshaping market dynamics and clinical adoption

Over the past several years, transformative shifts have altered both the competitive and clinical landscapes for bone cements and surgical glues, driven by material science breakthroughs, procedural migration, and heightened regulatory scrutiny. Innovations in bioactive formulations have advanced from proof-of-concept to routine clinical evaluation, enabling materials that promote osteointegration and provide controlled resorption profiles. At the same time, improvements in delivery mechanisms, such as injectable and moldable formats, have expanded the range of minimally invasive and outpatient procedures that can reliably utilize these products.

Concurrently, there has been a steady movement of select procedures from inpatient settings to ambulatory surgical centers and specialty clinics, prompted by cost containment pressures and the drive to reduce hospital length of stay. This migration has pushed suppliers to refine packaging, sterilization, and handling features to suit lower-acuity settings where space and instrumentation differ from traditional OR environments. Transitioning procedural venues has also highlighted the importance of product ease-of-use and predictable performance under constrained time windows.

Regulatory expectations have intensified, particularly around safety labeling for antibiotic-loaded products and clinical data supporting long-term outcomes. As a result, companies are investing more heavily in clinical evidence generation and post-market surveillance. These combined shifts - material innovation, procedural migration, and regulatory focus - are creating new avenues for competitive differentiation while raising the bar for market entry and sustained commercial success.

Assessing how recent tariff measures have prompted strategic supply chain reconfiguration, sourcing regionalization, and commercial contracting shifts across the sector

The introduction of tariffs and trade policy changes in 2025 has created a measurable inflection point for supply chain strategies across the bone cement and glue sector. Import duties on intermediate inputs and finished devices have increased landed costs for manufacturers that rely on cross-border production of polymers, active additives, and packaging materials. In response, firms are reassessing sourcing strategies while accelerating regionalization of manufacturing capacity to reduce exposure to tariff volatility and to safeguard delivery timelines to key clinical customers.

As procurement teams adapt to higher input costs, there is stronger emphasis on value-based contracting and longer-term supply agreements that lock in pricing and service levels. This has intensified negotiations with distributors and group purchasing organizations, which are themselves recalibrating supplier portfolios to prioritize manufacturers with secure, near-shore production footprints. Consequently, companies without diversified manufacturing nodes or those dependent on single-source suppliers are under pressure to either secure alternative suppliers or to invest in localized production capabilities.

The tariff environment has also catalyzed innovation in packaging and product design to optimize transport efficiency and reduce weight- or volume-based duties. In parallel, firms are increasingly exploring toll manufacturing and licensing arrangements with regional partners to maintain market continuity while bypassing certain trade barriers. These strategic responses are not only tactical cost mitigations but also long-term decisions that influence competitive positioning, time-to-market for new formulations, and the resilience of supply chains amid shifting trade policies.

In-depth segmentation analysis reveals how product chemistry, clinical application, end-user settings, technology types, and distribution choices drive differentiated adoption pathways

Segmentation analysis reveals nuanced performance characteristics and adoption pathways that vary by product chemistry, clinical application, end-user setting, technology class, and distribution model. In terms of product type, the market encompasses acrylic bone cement and calcium phosphate cement; the acrylic segment is distinguished by antibiotic-loaded formulations and non-antibiotic variants that cater to infection control protocols and standard fixation needs respectively, while calcium phosphate alternatives are offered in injectable and moldable forms that respond to preferences for minimally invasive delivery or intraoperative shaping.

When viewed through the lens of application, clinical demand is distributed across craniomaxillofacial, dental, and orthopedic specialties. Craniomaxillofacial indications focus on reconstructive surgery and trauma repair with an emphasis on contour restoration and fixation; dental applications span implantology and restorative procedures where biocompatibility and handling impact osseointegration; orthopedic uses cover fracture fixation, joint replacement, and spinal surgery, each with distinct mechanical and biological performance imperatives that inform material selection.

End-user differentiation is significant: ambulatory surgical centers-comprising multi-specialty and orthopedic centers-prioritize quick-setting, easy-to-handle systems that align with accelerated throughput, whereas hospitals, both private and public institutions, demand versatility across complex procedures and compatibility with institutional purchasing protocols. Specialty clinics, including dental clinics and outpatient rehabilitation centers, require smaller package formats and user-friendly delivery systems tailored to high-volume, outpatient workflows.

Technology segmentation separates bioactive approaches from PMMA-based platforms. Bioactive technologies include calcium phosphate and calcium silicate variants designed to interact with host tissue and promote healing, while PMMA-based solutions present high-viscosity and low-viscosity options chosen for their mechanical stability and handling characteristics. From a distribution perspective, direct sales arrangements-built on OEM relationships and tender contracts-favor large institutional customers, distributors operate through group purchasing organizations and independent channels to reach a broader base, and online channels, comprising e-commerce platforms and manufacturer websites, are increasingly important for small-volume purchasers and quick replenishment. Together, these segmentation axes create a matrix of demand signals that manufacturers and suppliers must decode to align product development, marketing, and sales strategies effectively.

Regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence adoption, regulatory priorities, and supply strategies

Regional dynamics materially influence both commercialization strategies and product development priorities. In the Americas, demand trends are shaped by a mature hospital infrastructure, expansive private hospital networks, and growing outpatient surgical capacity, which together create opportunities for both established PMMA-based products and emerging bioactive formulations that address infection control and osteointegration. The region's procurement sophistication encourages long-term supplier relationships and structured contracting mechanisms that reward evidence-backed performance and reliable supply chains.

In Europe, Middle East & Africa, regulatory harmonization and diverse healthcare models create a complex mosaic of adoption curves. Western European markets demand rigorous clinical data and often serve as launchpads for advanced bioactive materials, while markets in other parts of the region may emphasize cost-effectiveness and supply chain adaptability. Emerging markets within this region present growth potential driven by infrastructure investment and expanding access to surgical care, yet they require tailored distribution approaches and flexible pricing structures.

The Asia-Pacific region is characterized by a broad spectrum of market maturity, with high-volume centers in urban hubs adopting sophisticated materials and delivery systems, and peripheral settings prioritizing affordability and ease of use. Local manufacturing hubs and a thriving medtech innovation ecosystem in several countries are accelerating product localization and customization. Across all regions, supply chain resilience, regulatory alignment, and the ability to demonstrate clinical and economic value remain decisive factors for sustained adoption and market penetration.

Competitive landscape overview showing how incumbents, specialized innovators, and channel partners shape product differentiation and market access strategies

Competitive dynamics in the bone cement and surgical glue ecosystem are defined by a mixture of legacy manufacturers, specialty biomaterials firms, contract manufacturers, and innovative startups focused on next-generation bioactive chemistries. Established players benefit from entrenched relationships with large hospital systems, extensive commercial footprints, and experience with regulatory approvals across multiple jurisdictions. These incumbents often leverage scale to optimize manufacturing costs, invest in clinical evidence development, and offer bundled solutions that include instrumentation and training.

At the same time, midsized and emerging firms are differentiating through focused investments in niche technologies such as antibiotic-loaded cements with refined elution profiles, calcium phosphate systems designed for specific orthopedic niches, and high-precision delivery platforms that reduce intraoperative variability. Contract manufacturing organizations play an increasingly strategic role by enabling smaller innovators to scale production while managing quality systems and regulatory compliance.

Distribution partners, including national distributors and group purchasing organizations, act as gatekeepers to hospital formularies and ambulatory networks; their influence over purchasing decisions underscores the importance of channel strategies that balance direct sales relationships with broader distribution agreements. Partnerships and licensing arrangements are common as faster time-to-market and local regulatory alignment become priorities. Overall, competitive success hinges on a company's ability to demonstrate clinical differentiation, maintain supply continuity, and engage with stakeholders across procurement, clinical practice, and hospital leadership.

Actionable strategic priorities for manufacturers and suppliers to strengthen clinical differentiation, supply resilience, and commercial scalability in evolving care settings

Leaders in the bone cement and glue sector should adopt a multi-pronged strategy that addresses product excellence, supply chain resilience, and alignment with evolving clinical pathways. First, invest in clinical evidence programs that not only meet regulatory requirements but also generate real-world outcomes data demonstrating improvements in infection rates, implant stability, and patient recovery timelines. Such data supports differentiated value propositions during procurement negotiations and facilitates placement on hospital formularies and preferred vendor lists.

Second, diversify manufacturing and sourcing footprints to mitigate trade policy exposures and to ensure continuity of supply for critical hospital customers. This may include pursuing regional manufacturing partnerships, tolling agreements, or selective near-shoring to reduce lead times and tariff impacts. In tandem, optimize packaging and logistics to minimize transport costs and to meet the specific needs of ambulatory and outpatient settings where space and instrumentation differ from traditional operating theaters.

Third, refine commercial models to balance direct sales with distributor partnerships and digital channels. Direct engagement with large institutional buyers remains important for complex offerings, while distributors and online platforms can extend reach into smaller clinics and dental practices. Additionally, prioritize training and education programs that simplify product handling and demonstrate procedural efficiencies; clinicians value hands-on support and evidence-backed protocols that reduce intraoperative uncertainty.

Finally, pursue targeted R&D focused on user-centric product features such as adjustable setting times, improved radiopacity, and compatible delivery tools. Complement product development with strategic collaborations that accelerate clinical validation and regulatory approvals. Taken together, these actions will strengthen market positioning and create durable competitive advantage as clinical and procurement landscapes continue to evolve.

Robust mixed-methods research approach combining clinician interviews, supplier documentation analysis, and multi-source data triangulation to ensure actionable rigor

The research underpinning this analysis integrates qualitative and quantitative approaches to ensure comprehensive, evidence-based insights. Primary research consisted of structured interviews with clinicians across orthopedics, craniofacial surgery, and dentistry, procurement leaders from hospitals and ambulatory surgical centers, product managers from biomaterials companies, and distribution executives. These conversations provided direct perspectives on clinical performance expectations, procurement decision drivers, and operational constraints that shape product selection.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, and publicly available clinical study summaries to validate material properties, performance claims, and safety profiles. In addition, supplier documentation, product IFUs, and clinical technique guides were analyzed to assess handling characteristics and usage protocols. Data triangulation combined insights from primary interviews with secondary sources to identify convergent themes and to reconcile conflicting viewpoints.

Analytical techniques included thematic coding of qualitative transcripts, comparative feature mapping across product types and technologies, and scenario analysis to evaluate the impact of supply chain disruptions and policy shifts. Quality assurance steps encompassed cross-validation with multiple interviewees, peer review of draft findings by subject matter experts, and adherence to transparent documentation standards for data sources and methodological assumptions. This robust methodology ensures the findings offer both practical relevance and analytical rigor for stakeholders seeking to inform strategy and operational planning.

Strategic closing perspective highlighting the convergence of clinical performance, procurement priorities, and supply resilience that will determine future market leaders

In closing, the bone cement and surgical adhesive market is transitioning toward solutions that blend reliable mechanical performance with biological activity and practical handling for diverse procedural settings. This evolution is driven by clinical demand for improved outcomes, by procurement pressures that emphasize value and supply resilience, and by regulatory expectations that prioritize patient safety and evidence-based practice. Stakeholders that align product development with clinical workflows and that invest in scalable, regionally resilient supply models will be best positioned to capture emerging opportunities.

As the sector advances, success will increasingly depend on the ability to translate material science into executable clinical advantages-reducing infection risk, enhancing fixation, and improving patient recovery-while simultaneously navigating the complexities of distribution and procurement. Collaborative approaches that engage clinicians early in design, partner with regional manufacturers or contract manufacturers to secure supply, and employ data-driven value propositions will differentiate suppliers in a competitive landscape. Overall, the outlook favors those who can combine demonstrable clinical value with operational excellence and strategic agility.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bone Cement & Glue Market, by Product Type

• 8.1. Acrylic Bone Cement
  • 8.1.1. Antibiotic Loaded
  • 8.1.2. Non Antibiotic Loaded
• 8.2. Calcium Phosphate Cement
  • 8.2.1. Injectable
  • 8.2.2. Moldable

9. Bone Cement & Glue Market, by Technology

• 9.1. Bioactive
  • 9.1.1. Calcium Phosphate
  • 9.1.2. Calcium Silicate
• 9.2. PMMA Based
  • 9.2.1. High Viscosity
  • 9.2.2. Low Viscosity

10. Bone Cement & Glue Market, by Application

• 10.1. Craniomaxillofacial
  • 10.1.1. Reconstructive Surgery
  • 10.1.2. Trauma Repair
• 10.2. Dental
  • 10.2.1. Implantology
  • 10.2.2. Restorative
• 10.3. Orthopedic
  • 10.3.1. Fracture Fixation
  • 10.3.2. Joint Replacement
  • 10.3.3. Spinal Surgery

11. Bone Cement & Glue Market, by End User

• 11.1. Ambulatory Surgical Centers
  • 11.1.1. Multi Specialty
  • 11.1.2. Orthopedic Centers
• 11.2. Hospitals
  • 11.2.1. Private Hospital
  • 11.2.2. Public Hospital
• 11.3. Specialty Clinics
  • 11.3.1. Dental Clinics
  • 11.3.2. Outpatient Rehab

12. Bone Cement & Glue Market, by Distribution Channel

• 12.1. Direct Sales
  • 12.1.1. OEM Relationships
  • 12.1.2. Tender Contracts
• 12.2. Distributors
  • 12.2.1. Group Purchasing Organizations
  • 12.2.2. Independent Distributors
• 12.3. Online Channels
  • 12.3.1. E Commerce Platforms
  • 12.3.2. Manufacturer Website

13. Bone Cement & Glue Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Bone Cement & Glue Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Bone Cement & Glue Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Bone Cement & Glue Market

17. China Bone Cement & Glue Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. B. Braun Melsungen AG
• 18.6. DePuy Synthes, Inc.
• 18.7. DJO Global, Inc.
• 18.8. Heraeus Medical GmbH
• 18.9. Medtronic plc
• 18.10. Paragon 28, LLC
• 18.11. Smith & Nephew plc
• 18.12. Stryker Corporation
• 18.13. TEI Biosciences, Inc.
• 18.14. Zimmer Biomet Holdings, Inc.